| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| CA125 | HOTAvitag CA5-H82F4 | Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $415.00 25ug | ||
| CA125 | HOTAvitag CA5-H82F8 | Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $415.00 25ug | ||
| CA125 | HOT CA5-H52H6 | Human CA125 / MUC16 (13810-14451) Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 100ug | ||
| CA125 | Cynomolgus CA125 / MUC16 Protein, His Tag, low endotoxin (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | |||
| CA125 | Avitag CA5-C82E9 | Biotinylated Cynomolgus CA125 / MUC16 Protein, His,Avitag™ (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | ||
| CA125 | Mouse CA125 / MUC16 Protein, His Tag (MALS verified) | Mouse | HEK293 | ![]() | MALS | $360.00 100ug | |||
| CA125 | Rabbit CA125 / MUC16 Protein, His Tag | Rabbit | HEK293 | ![]() | SDS-PAGE | $360.00 100ug | |||
| CA125 | Rat CA125 Protein, His Tag (MALS verified) | Rat | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Oregovomab | B43.13 | Phase 3 Clinical | Paladin Pharma | Abdominal Neoplasms; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms | Details |
| EB-NK-FM (FRalpha/MUC16) | EB-NK-FM | Phase 2 Clinical | Beijing Biotech | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Details |
| EB-NK-MM (MSLN/MUC16) | EB-NK-MM | Phase 2 Clinical | Beijing Biotech | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Details |
| LBL-033 | LBL-033 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Neoplasms | Details |
| REGN-5668 | REGN-5668 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | Details |
| Ubamatamab | REGN-4018 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | Details |
| PRGN-3005 | PRGN-3005 | Phase 1 Clinical | Precigen Inc | Esophageal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Uterine Cervical Neoplasms | Details |
| GB-5267 | GB-5267 | Phase 1 Clinical | Generate Biomedicines Inc | Ovarian Neoplasms | Details |
| HWK-016 | HWK-016 | Phase 1 Clinical | Wuxi Biologics Co Ltd | Endometrial Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | Details |
| JCAR-020 | JCAR-020 | Phase 1 Clinical | Eureka Therapeutics Inc, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center | Solid tumours | Details |
| Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy(Regeneron Pharmaceutical) | 27T-51; 27T51 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Details |
